Zydus Cadila launches 'most affordable' gliptin for diabetics in India

Indian drugmaker Zydus Cadila (BSE: 532321) has launched its Tenglyn (teneligliptin 20mg) tablets, which belongs to a new class of oral anti-diabetic agents dubbed gliptins.

With an aim to make this important therapy affordable and accessible to diabetic patients, Tenglyn is being priced at just 7 rupees ($0.11) per tablet which is almost a sixth the price at which the gliptins were initially launched in India.

Gliptins have shown promise in achieving glycemic control without deteriorating beta cell function and is one of the most recent advancements in diabetes care and management. Research in the field of anti-diabetic therapy seeks to address the problems of hypoglycemia, gastro-intestinal side effects, lactic acidosis, weight gain, cardiovascular risks, etc, which pose a major challenge in the treatment of diabetes.